...
首页> 外文期刊>Journal of Clinical Microbiology >Testing Susceptibility of Multidrug-Resistant Mycobacterium tuberculosis to Second-Line Drugs by Use of Blood Agar
【24h】

Testing Susceptibility of Multidrug-Resistant Mycobacterium tuberculosis to Second-Line Drugs by Use of Blood Agar

机译:通过使用血琼脂测试耐多药结核分枝杆菌对二线药物的敏感性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In this study, the susceptibilities of 35 multidrug-resistant (MDR) Mycobacterium tuberculosis clinical isolates to second-line drugs, including kanamycin (KM), rifabutin (RBU), ofloxacin (OFX), p-aminosalicylic acid (PAS), capreomycin (CAP), clofazimine (CFM), and ethionamide (ETH), were investigated on blood agar according to CLSI recommendations. Compared with the results of the Bactec 460 TB system, agreement was 100, 100, 97, 100, 100, 100, and 86% for KM, RBU, OFX, PAS, CAP, CFM, and ETH, respectively. Compared with the results of the proportion method, agreement was 100, 100, 97, 100, 97, 100, and 77% for KM, RBU, OFX, PAS, CAP, CFM, and ETH, respectively.
机译:在这项研究中,对35种多重耐药(MDR)结核分枝杆菌临床分离株对二线药物(包括卡那霉素(KM),利福布汀(RBU),氧氟沙星(OFX)和)的敏感性根据CLSI的建议,在血琼脂上研究了对氨基水杨酸(PAS),卡普霉素(CAP),氯法齐明(CFM)和乙酰胺(ETH)。与Bactec 460 TB系统的结果相比,KM,RBU,OFX,PAS,CAP,CFM和ETH的一致性分别为100%,100%,97%,100%,100%,100%和86%。与比例法的结果相比,KM,RBU,OFX,PAS,CAP,CFM和ETH的一致性分别为100%,100%,97%,100%,97%,100%和77%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号